Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer - PubMed (original) (raw)

. 2011 Oct;25(10):3325-35.

doi: 10.1096/fj.11-182287. Epub 2011 Jun 17.

Christian Fischer, Katharina M Detjen, Svenja Rieke, Georg Hilfenhaus, Zofia von Marschall, Michael Böhmig, Inga Koch, Jenny Kehrberger, Peter Hauff, Karl Heinz Thierauch, Frauke Alves, Bertram Wiedenmann, Arne Scholz

Affiliations

• PMID: 21685330
• DOI: 10.1096/fj.11-182287

Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer

Petra Schulz et al. FASEB J. 2011 Oct.

Abstract

Lymphatic metastasis constitutes a critical route of disease dissemination, which limits the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). As lymphangiogenesis has been implicated in stimulation of lymphatic metastasis by vascular endothelial growth factor-C (VEGF-C) and VEGF-D, we studied the effect of the angioregulatory growth factor angiopoietin-2 (Ang-2) on PDAC progression. Ang-2 was found to be expressed in transformed cells of human PDAC specimens, with corresponding Tie-2 receptors present on blood and lymphatic endothelium. In vitro in PDAC cells, Ang-2 was subject to autocrine/paracrine TGF-β stimulation (2-fold induction, P=0.0106) acting on the -61- to +476-bp element of the human Ang-2 promoter. In turn, Ang-2 regulated the expression of genes involved in cell motility and tumor suppression. Orthotopic PDAC xenografts with forced expression of Ang-2, but not Ang-1, displayed increased blood and lymphatic vessel density, and an enhanced rate of lymphatic metastasis (6.7- to 9.1-fold, P<0.01), which was prevented by sequestration of Ang-2 via coexpression of soluble Tie-2. Notably, elevated circulating Ang-2 in patients with PDAC correlated with the extent of lymphatic metastasis. Furthermore, median survival was reduced from 28.4 to 7.7 mo in patients with circulating Ang-2 ≥ 75th percentile (P=0.0005). These findings indicate that Ang-2 participates in the control of lymphatic metastasis, constitutes a noninvasive prognostic biomarker, and may provide an accessible therapeutic target in PDAC.

PubMed Disclaimer

Similar articles

• Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
  Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A. Detjen KM, et al. Clin Cancer Res. 2010 Jan 15;16(2):420-9. doi: 10.1158/1078-0432.CCR-09-1924. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068079
• Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis.
  Sipos B, Kojima M, Tiemann K, Klapper W, Kruse ML, Kalthoff H, Schniewind B, Tepel J, Weich H, Kerjaschki D, Klöppel G. Sipos B, et al. J Pathol. 2005 Nov;207(3):301-12. doi: 10.1002/path.1840. J Pathol. 2005. PMID: 16161179
• Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
  Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. Zhang L, et al. Cancer Res. 2003 Jun 15;63(12):3403-12. Cancer Res. 2003. PMID: 12810677
• The role of Ang/Tie signaling in lymphangiogenesis.
  Wu X, Liu N. Wu X, et al. Lymphology. 2010 Jun;43(2):59-72. Lymphology. 2010. PMID: 20848993 Review.
• Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.
  Scavelli C, Vacca A, Di Pietro G, Dammacco F, Ribatti D. Scavelli C, et al. Leukemia. 2004 Jun;18(6):1054-8. doi: 10.1038/sj.leu.2403355. Leukemia. 2004. PMID: 15057248 Review.

Cited by

• Lymph Node Metastasis in Gastrointestinal Carcinomas: A View from a Proteomics Perspective.
  Jain V, Sakhuja P, Agarwal AK, Sirdeshmukh R, Siraj F, Gautam P. Jain V, et al. Curr Oncol. 2024 Aug 2;31(8):4455-4475. doi: 10.3390/curroncol31080333. Curr Oncol. 2024. PMID: 39195316 Free PMC article. Review.
• Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer.
  Göhrig A, Hilfenhaus G, Rosseck F, Welzel M, Moser B, Barbone G, Kunze CA, Rein J, Wilken G, Böhmig M, Malinka T, Tacke F, Bahra M, Detjen KM, Fischer C. Göhrig A, et al. J Exp Clin Cancer Res. 2024 May 30;43(1):153. doi: 10.1186/s13046-024-03066-z. J Exp Clin Cancer Res. 2024. PMID: 38816706 Free PMC article.
• Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review.
  Li JJ, Mao JX, Zhong HX, Zhao YY, Teng F, Lu XY, Zhu LY, Gao Y, Fu H, Guo WY. Li JJ, et al. World J Hepatol. 2024 Apr 27;16(4):537-549. doi: 10.4254/wjh.v16.i4.537. World J Hepatol. 2024. PMID: 38689749 Free PMC article. Review.
• The possible dual role of Ang-2 in the prognosis of pancreatic cancer.
  Roos-Mattila M, Kaprio T, Mustonen H, Hagström J, Saharinen P, Haglund C, Seppänen H. Roos-Mattila M, et al. Sci Rep. 2023 Oct 31;13(1):18725. doi: 10.1038/s41598-023-45194-0. Sci Rep. 2023. PMID: 37907568 Free PMC article.
• Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.
  Yang S, Zou X, Li J, Yang H, Zhang A, Zhu Y, Zhu L, Zhang L. Yang S, et al. Front Immunol. 2022 Sep 12;13:1010434. doi: 10.3389/fimmu.2022.1010434. eCollection 2022. Front Immunol. 2022. PMID: 36172371 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal